May 5, 2020 / 5:12 AM / 22 days ago

BRIEF-Libtayo (Cemiplimab) Shows Clinically-Meaningful And Durable Responses In Second-Line Advanced Basal Cell Carcinoma

May 5 (Reuters) - Regeneron Pharmaceuticals Inc:

* LIBTAYO (CEMIPLIMAB) SHOWS CLINICALLY-MEANINGFUL AND DURABLE RESPONSES IN SECOND-LINE ADVANCED BASAL CELL CARCINOMA

* OBJECTIVE RESPONSES SEEN IN APPROXIMATELY 29% OF PATIENTS WITH LOCALLY ADVANCED BASAL CELL CARCINOMA (BCC)

* IN A PRELIMINARY ANALYSIS, OBJECTIVE RESPONSES SEEN IN 21% OF PATIENTS WITH METASTATIC BCC

* REGENERON AND SANOFI PLAN REGULATORY SUBMISSIONS IN 2020

* 85% OF PATIENTS WHO RESPONDED TO LIBTAYO MAINTAINED THEIR RESPONSE FOR AT LEAST ONE YEAR Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below